DiscoverThe AI in Business PodcastAI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte
AI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte

AI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte

Update: 2024-02-23
Share

Description

Today’s guest is Andrew Bolt, Partner at Deloitte. He joins Emerj CEO and Head of Research Daniel Faggella on today’s podcast to talk about challenges in R&D  for life sciences. While productivity has remained stagnant for the last 10-15 years, advances in AI-enhanced protein structure prediction are revolutionizing drug targeting and the very infrastructure of recruiting patients for clinical trials. Later, the two postulate on the ways AI can expedite regulatory compliance in pharmaceutical R&D in similar ways. Find out more about sponsored content and how to engage with the Emerj audience at emerj.com/ad1.

Comments 
In Channel
loading
Download from Google Play
Download from App Store
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

AI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte

AI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte